Research

Receptor Tyrosine Kinase (RTK) signalling can be a positive driving force for cell proliferation, survival and migration but it is kept under tight control via feedback loops. In cancer, these controls can be bypassed by a variety of mechanisms and we are investigating how this happens.

We focus on breast and pancreatic cancer, using 2-D and 3-D cell-based models to investigate how cellular behaviour changes when cell signalling is altered. We collaborate with clinical colleagues to determine the translational significance of our findings through analysis of patient samples.

Our current research aims:

1. Modelling breast cancer development in 3D culture

3D modelling fulfils a critical role in research, allowing for complex cell behaviour and interactions to be studied in physiomimetic conditions. We have used the Breast Cancer Now Tissue Bank, an invaluable resource of primary cells isolated directly from patients, to interrogate the interactions between myoepithelial and luminal cells in 3D using collagen gels. Using lentiviral transduction of isolated cells, we have developed a model that allows us to study early events in breast cancer development, to help understand how breast cancer progresses, with the ultimate aim of improving early diagnosis and treatment.

We have a number of projects investigating protease dependent activities, proteomic approaches to understanding cross-talk, impact of the innate immune system and RTK crosstalk with cannabinoid receptors.

2. Understanding the molecular basis of pancreatic cancer invasion

Using advanced 3D cell based models we have identified a number of exciting new pathways implicated in stromal-led invasion in pancreatic cancer. We are investigating protease dependent activities, RTK-mediated pathways and purinergic signalling to identify novel biomarkers of disease progression and new targets for therapeutic intervention.

3. Targeting FGFR-mediated cellular crosstalk in cancer

Fibroblast Growth Factor Receptor (FGFR) mutations are key drivers in a number of cancers, where dependency on oncogenic FGFR signalling makes FGFRs attractive targets for targeted therapies. We have worked extensively on endometrial, cervical breast and pancreatic cancer models, showing FGF signalling to play a critical role in cell migration and survival.

We have discovered that, rather than signalling from the cell surface or within endosomes, FGFRs can be proteolytically cleaved following activation and that the cytoplasmic portion of the receptor can traffic to the nucleus and regulate gene transcription. We have identified this behaviour in invasive breast cancer cells both in vitro and in vivo. We have shown that nuclear FGFR signalling is a critical mediator of cancer-stroma cross-talk in pancreatic cancer, and we are exploring the therapeutic potential of FGFR inhibition in blocking pancreatic cancer progression.

For more information, please visit www.groselab.com

Other Activities

• Dean for Global Engagement, Faculty of Medicine & Dentistry, Queen Mary University of London
• Honorary Professor - Wenzhou University, China
• Breast Cancer Now grants committee
• Irish Cancer Society - Grants Review Panel Member
• National Science Centre, Poland - Expert Panel Member
• Commonwealth Scholarship Commission - Academic Adviser Panel
• British Association for Cancer Research executive committee
• Barts Pancreas Tissue Bank – Chair of Tissue Access Committee

Major Funding

• 2019-2023- Cancer Research UK, Myoepithelial degradome in the progression of DCIS to invasive breast cancer, £473,002
• 2019-2023- Barts Charity, Exploring the role of adenosine axis in the tumour microenvironment of pancreatic cancer, £104,971
• 2021-2022- Barts Charity, Deconvoluting cellular crosstalk in pancreatic cancer invasion, £49,511
• 2018-2022- Breast Cancer Now, Myoepithelial/luminal cross-talk in the progression of DCIS to invasive breast cancer, £201,816
• 2009-2010- Medical Research Council, Tumour suppressive function of Fgfr2b, £343,676.00

Recent Publications

Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment Jomrich G, Kollmann D, Ramazanova D et al. European Journal of Surgical Oncology (2022) 48(7) 383-390

Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion Murray ER, Menezes S, Henry JC et al. Cell Reports (2022) 38(7)

The Obscure Potential of AHNAK2. Zardab M, Stasinos K, Grose RP et al. Cancers (Basel) (2022) 14(2)
https://www.ncbi.nlm.nih.gov/pubmed/35158796

FGF signalling facilitates cervical cancer progression Mahmood HTNA, Tomas Bort E, Walker AJ et al. The Federation of European Biochemical Societies (FEBS) Journal (2022) (1)

Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy Jomrich G, Kollmann D, Wilfing L et al. European Surgery - Acta Chirurgica Austriaca (2021) 53(7) 287-293

Biological significance and targeting of the fgfr axis in cancer Chioni AM, Grose RP Cancers (2021) 13(7)

Tumour microenvironment 3D-modelling: simplicity to complexity and back again Carter EP, Roozitalab R, Gibson SV et al. Trends in Cancer (2021) 7(7) 1033-1046

Quantitative super‐resolution imaging for the analysis of GPCR oligomerization Joseph MD, Bort ET, Grose RP et al. Biomolecules (2021) 11(7)

Centrosome amplification mediates small extracellular vesicle secretion via lysosome disruption Adams SD, Csere J, D'angelo G et al. Current Biology (2021) 31(7) 1403-1416.e7

Dissecting fgf signalling to target cellular crosstalk in pancreatic cancer Carter EP, Coetzee AS, Bort ET et al. Cells (2021) 10(7)

Team

Postdoctoral Researchers

• Dr Edward Carter
• Dr Lucía Rodríguez Fernández
• Dr Kubra Yoneten

PhD Students

• Shayin Gibson
• Elena Tomas Bort
• Reza Roozitalab
• Nick Roth
• Qiaoying Wang
• Akil Gani

Biography

• 1990-91: Research assistant at Amersham. Developing ELISAs for HIV testing
• 1991-94: BSc in Zoology (University of Bristol)
• 1994-95: Research Associate at Pfizer Central Research. Molecular Sciences Department
• 1995-99: PhD (University College London). Molecular basis of embryonic wound repair (Prof Paul Martin)
• 1999-2001: Postdoctoral researcher (ETH Zurich). Genetically modified mouse models of wound healing (Prof Sabine Werner)
• 2001-2004: Postdoctoral Fellow (CR-UK LRI). FGF signalling in cancer (Dr Clive Dickson)
• 2004-present: Group leader at Barts Cancer Institute